481.59
price up icon1.19%   5.68
after-market アフターアワーズ: 481.00 -0.59 -0.12%
loading
前日終値:
$475.91
開ける:
$475.19
24時間の取引高:
1.36M
Relative Volume:
1.15
時価総額:
$63.13B
収益:
$2.46B
当期純損益:
$-319.09M
株価収益率:
-195.22
EPS:
-2.4669
ネットキャッシュフロー:
$-52.09M
1週間 パフォーマンス:
+3.59%
1か月 パフォーマンス:
+7.62%
6か月 パフォーマンス:
+87.25%
1年 パフォーマンス:
+69.16%
1日の値動き範囲:
Value
$467.09
$482.73
1週間の範囲:
Value
$456.90
$485.36
52週間の値動き範囲:
Value
$205.87
$495.55

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name
名前
Alnylam Pharmaceuticals Inc
Name
セクター
Healthcare (1136)
Name
電話
(617) 551-8200
Name
住所
675 WEST KENDALL STREET, CAMBRIDGE, MA
Name
職員
2,230
Name
Twitter
@alnylam
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
ALNY's Discussions on Twitter

ALNY を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
481.59 62.38B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
417.21 108.30B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
652.91 69.37B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
821.97 51.50B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
166.95 34.94B 398.11M -1.03B -868.57M -5.7032

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-08-04 アップグレード Oppenheimer Perform → Outperform
2025-08-04 アップグレード Wolfe Research Underperform → Peer Perform
2025-07-30 再開されました Raymond James Outperform
2025-07-21 開始されました Truist Buy
2025-03-31 開始されました Redburn Atlantic Buy
2025-03-24 アップグレード JP Morgan Neutral → Overweight
2024-11-12 ダウングレード Wolfe Research Peer Perform → Underperform
2024-10-16 開始されました Scotiabank Sector Outperform
2024-08-16 アップグレード Goldman Neutral → Buy
2024-02-16 ダウングレード Goldman Buy → Neutral
2024-02-15 開始されました Wolfe Research Peer Perform
2023-12-08 開始されました Wells Fargo Equal Weight
2023-10-11 ダウングレード Oppenheimer Outperform → Perform
2023-09-29 開始されました Raymond James Outperform
2023-05-05 アップグレード BMO Capital Markets Market Perform → Outperform
2023-04-26 開始されました SMBC Nikko Neutral
2023-03-21 開始されました Bernstein Outperform
2023-01-18 開始されました Canaccord Genuity Buy
2022-09-09 再開されました Morgan Stanley Equal-Weight
2022-07-13 開始されました Cantor Fitzgerald Neutral
2022-06-27 ダウングレード Guggenheim Buy → Neutral
2022-06-07 開始されました William Blair Outperform
2022-04-25 ダウングレード Morgan Stanley Overweight → Equal-Weight
2022-03-01 開始されました Citigroup Buy
2022-02-03 アップグレード Guggenheim Neutral → Buy
2022-01-03 アップグレード Piper Sandler Neutral → Overweight
2021-11-22 アップグレード Goldman Neutral → Buy
2021-11-22 アップグレード RBC Capital Mkts Sector Perform → Outperform
2021-11-01 アップグレード Oppenheimer Perform → Outperform
2021-10-04 アップグレード UBS Neutral → Buy
2021-08-04 ダウングレード Piper Sandler Overweight → Neutral
2021-02-22 ダウングレード Guggenheim Buy → Neutral
2021-02-12 ダウングレード Citigroup Buy → Neutral
2021-02-12 繰り返されました H.C. Wainwright Buy
2021-01-25 ダウングレード BMO Capital Markets Outperform → Market Perform
2020-09-30 再開されました Berenberg Hold
2020-09-08 開始されました Citigroup Buy
2020-08-11 ダウングレード Oppenheimer Outperform → Perform
2020-05-13 開始されました RBC Capital Mkts Sector Perform
2020-05-07 ダウングレード JP Morgan Overweight → Neutral
2020-04-24 再開されました Evercore ISI Outperform
2020-03-19 開始されました Berenberg Buy
2019-12-19 繰り返されました Chardan Capital Markets Buy
2019-11-20 開始されました Oppenheimer Outperform
2019-11-13 開始されました BofA/Merrill Buy
2019-05-23 再開されました Goldman Neutral
2019-04-12 開始されました Evercore ISI Outperform
2019-03-06 アップグレード Evercore ISI In-line → Outperform
2019-03-05 アップグレード Morgan Stanley Equal-Weight → Overweight
2019-01-23 開始されました UBS Neutral
2018-10-01 開始されました Cantor Fitzgerald Overweight
2018-08-13 繰り返されました Stifel Buy
2018-08-07 アップグレード Stifel Hold → Buy
2018-05-04 繰り返されました Stifel Hold
2018-03-28 開始されました Evercore ISI In-line
すべてを表示

Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース

pulisher
08:15 AM

How to monitor Alnylam Pharmaceuticals Inc. with trend dashboardsQuarterly Market Summary & Stepwise Entry and Exit Trade Signals - newser.com

08:15 AM
pulisher
08:04 AM

Is Alnylam Pharmaceuticals Inc. reversing from oversold territory2025 Top Gainers & Smart Investment Allocation Tips - newser.com

08:04 AM
pulisher
08:02 AM

How dovish Fed policy supports Alnylam Pharmaceuticals Inc. (DUL) stockJuly 2025 Trade Ideas & AI Based Buy and Sell Signals - newser.com

08:02 AM
pulisher
07:52 AM

Combining machine learning predictions for Alnylam Pharmaceuticals Inc.Weekly Profit Summary & Fast Exit and Entry Strategy Plans - newser.com

07:52 AM
pulisher
07:08 AM

How to recover losses in Alnylam Pharmaceuticals Inc. stockMarket Risk Summary & Fast Gain Swing Alerts - newser.com

07:08 AM
pulisher
06:16 AM

What data driven models say about Alnylam Pharmaceuticals Inc.’s futureGlobal Markets & High Return Stock Watch Alerts - newser.com

06:16 AM
pulisher
05:41 AM

RNAi Technology Market See Incredible Growth 2025-2032 | Alnylam Pharmaceuticals, OriGene Technologies, Inc. - openPR.com

05:41 AM
pulisher
04:55 AM

Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain revenue momentumPortfolio Update Summary & Real-Time Chart Pattern Alerts - newser.com

04:55 AM
pulisher
04:35 AM

How risky is Alnylam Pharmaceuticals Inc. (DUL) stock compared to peersJuly 2025 Macro Moves & Entry and Exit Point Strategies - newser.com

04:35 AM
pulisher
04:17 AM

Will Alnylam Pharmaceuticals Inc. continue its uptrendJuly 2025 Update & Free Long-Term Investment Growth Plans - newser.com

04:17 AM
pulisher
Oct 28, 2025

PD-1 and PD-L1 Inhibitors Clinical Landscape, Key Companies, Therapeutic Evaluation, Treatment Approaches, and Pipeline Insights | Hoffmann-La Roche, PTC Therapeutics, Annexon, Alnylam Pharmaceuticals - Barchart.com

Oct 28, 2025
pulisher
Oct 28, 2025

Is Alnylam Pharmaceuticals Inc. (DUL) stock vulnerable to rate hikesJuly 2025 Retail & High Win Rate Trade Tips - Fundação Cultural do Pará

Oct 28, 2025
pulisher
Oct 28, 2025

Why Alnylam Pharmaceuticals Inc. stock is recommended by analystsWeekly Trend Summary & Comprehensive Market Scan Insights - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Exploring Analyst Estimates for Alnylam (ALNY) Q3 Earnings, Beyond Revenue and EPS - Yahoo Finance

Oct 28, 2025
pulisher
Oct 28, 2025

Hypertension Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Addpharma Inc., Alnylam Therapeutics, ORPHAI THERAPEUTICS, 35Pharma Inc - Barchart.com

Oct 28, 2025
pulisher
Oct 28, 2025

Alnylam Pharmaceuticals (ALNY) extending rally in final stage from April-2025 low - FXStreet

Oct 28, 2025
pulisher
Oct 28, 2025

What downside risks could hit Alnylam Pharmaceuticals Inc. (DUL) stock2025 Volatility Report & Free Weekly Watchlist of Top Performers - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

What RSI levels show for Alnylam Pharmaceuticals Inc. (DUL) stockJuly 2025 Levels & Verified Chart Pattern Trade Signals - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Why global investors buy Alnylam Pharmaceuticals Inc. (DUL) stock2025 Investor Takeaways & Free Fast Entry Momentum Trade Alerts - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain institutional flows2025 Trading Recap & Stock Portfolio Risk Control - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Is it time to cut losses on Alnylam Pharmaceuticals Inc.Treasury Yields & Smart Investment Allocation Insights - newser.com

Oct 28, 2025
pulisher
Oct 27, 2025

What to do if you’re stuck in Alnylam Pharmaceuticals Inc.Trade Ideas & Weekly Top Gainers Trade List - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Has Alnylam Pharmaceuticals Inc. found a price floorEarnings Miss & High Return Trade Opportunity Guides - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Alnylam Pharmaceuticals Inc Stock Analysis and ForecastMarket Liquidity Analysis & Free Rapid Profit Acceleration - earlytimes.in

Oct 27, 2025
pulisher
Oct 27, 2025

Is Alnylam Pharmaceuticals Inc. (DUL) stock overpriced at current multiplesTrade Analysis Summary & Daily Profit Maximizing Tips - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Is Alnylam Pharmaceuticals Inc. stock resilient to inflationJuly 2025 Action & High Accuracy Swing Entry Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Bernstein previews biotech earnings, expects Alnylam and Regeneron to beat - Investing.com

Oct 27, 2025
pulisher
Oct 27, 2025

Using data filters to optimize entry into Alnylam Pharmaceuticals Inc.Exit Point & Intraday High Probability Setup Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Published on: 2025-10-27 00:10:20 - newser.com

Oct 27, 2025

Alnylam Pharmaceuticals Inc (ALNY) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Alnylam Pharmaceuticals Inc (ALNY) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Greenstreet Yvonne
Chief Executive Officer
Oct 02 '25
Sale
452.05
8,924
4,034,085
65,409
Tanguler Tolga
EVP, Chief Commercial Officer
Oct 02 '25
Sale
452.05
1,405
635,126
27,438
Fitzgerald Kevin Joseph
CSO & EVP, Head of Research
Oct 02 '25
Sale
452.05
2,441
1,103,451
25,231
Garg Pushkal
EVP Chief R&D
Oct 03 '25
Sale
451.48
3,022
1,364,387
20,221
Garg Pushkal
EVP Chief R&D
Oct 02 '25
Sale
452.05
2,937
1,327,675
23,243
$652.91
price down icon 0.24%
$821.97
price down icon 1.72%
$166.95
price up icon 1.00%
biotechnology ONC
$314.85
price down icon 0.63%
$103.35
price down icon 1.60%
大文字化:     |  ボリューム (24 時間):